The Latin America, Middle East and Africa Cancer Gene Therapy Market would witness market growth of 26.5% CAGR during the forecast period (2022-2028).
Several unmet medical needs for cancer treatment have prompted cancer gene therapy research and development. The global cancer gene therapy market is being driven by a number of factors, including rising cancer prevalence, increased government activities, and increased funding from numerous governments and non-government organizations. Furthermore, the cancer gene therapy market is being driven by the ethical acceptability of gene therapy for disease treatment and the increasing popularity of DNA vaccines. However, the global market for cancer gene therapy is being held back by a lack of awareness and the high expense of treatment.
The development of some novel therapies with a higher success rate is projected to provide a promising future for cancer gene therapy. Furthermore, despite the high costs of R&D, pharmaceutical corporations are becoming more interested in this subject. This is predicted to have a significant impact on the cancer gene therapy business. The majority of cancer gene therapy products are now in clinical trials. Following the clearance or success of these drugs in clinical trials, the market is likely to grow.
The Brazzaville Declaration on Noncommunicable Disease Prevention and Control in the WHO African Region, adopted in 2011, reaffirmed African governments' understanding of the growing health threat posed by non-communicable diseases (NCDs), such as cancer. The signatories agreed to develop prevention and control strategies, strengthen their health systems to reduce the burden of NCDs, source the funds needed to fight these diseases, and facilitate their national health information systems to produce information on NCDs and their risk factors, among other things. However, progress is still gradual in this direction. Only 17 of the 46 nations that responded to a WHO survey in the African region in 2010 had operational cancer policies, strategies, or action plans.
The Brazil market dominated the LAMEA Cancer Gene Therapy Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $87.5 million by 2028. The Argentina market anticipated to grow at a CAGR of 27.2% during (2022 - 2028). Additionally, The UAE market would showcase a CAGR of 26.2% during (2022 - 2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Cancer Gene Therapy Market is Predict to reach $5 Billion by 2028, at a CAGR of 21.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy, and
- Gene Transfer
By End User
- Hospitals
- Diagnostic centers
- Research Institutes
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cancer Gene Therapy Market, by Therapy
1.4.2 LAMEA Cancer Gene Therapy Market, by End User
1.4.3 LAMEA Cancer Gene Therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Cancer Gene Therapy Market by Therapy
3.1 LAMEA Gene Induced Immunotherapy Market by Country
3.2 LAMEA Oncolytic Virotherapy Market by Country
3.3 LAMEA Gene Transfer Market by Country
Chapter 4. LAMEA Cancer Gene Therapy Market by End User
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Diagnostic centers Market by Country
4.3 LAMEA Research Institutes Market by Country
Chapter 5. LAMEA Cancer Gene Therapy Market by Country
5.1 Brazil Cancer Gene Therapy Market
5.1.1 Brazil Cancer Gene Therapy Market by Therapy
5.1.2 Brazil Cancer Gene Therapy Market by End User
5.2 Argentina Cancer Gene Therapy Market
5.2.1 Argentina Cancer Gene Therapy Market by Therapy
5.2.2 Argentina Cancer Gene Therapy Market by End User
5.3 UAE Cancer Gene Therapy Market
5.3.1 UAE Cancer Gene Therapy Market by Therapy
5.3.2 UAE Cancer Gene Therapy Market by End User
5.4 Saudi Arabia Cancer Gene Therapy Market
5.4.1 Saudi Arabia Cancer Gene Therapy Market by Therapy
5.4.2 Saudi Arabia Cancer Gene Therapy Market by End User
5.5 South Africa Cancer Gene Therapy Market
5.5.1 South Africa Cancer Gene Therapy Market by Therapy
5.5.2 South Africa Cancer Gene Therapy Market by End User
5.6 Nigeria Cancer Gene Therapy Market
5.6.1 Nigeria Cancer Gene Therapy Market by Therapy
5.6.2 Nigeria Cancer Gene Therapy Market by End User
5.7 Rest of LAMEA Cancer Gene Therapy Market
5.7.1 Rest of LAMEA Cancer Gene Therapy Market by Therapy
5.7.2 Rest of LAMEA Cancer Gene Therapy Market by End User
Chapter 6. Company Profiles
6.1 Novartis AG
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Amgen, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
6.6.1 Company overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Genelux Corporation
6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses
TABLE 1 LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 4 LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 5 LAMEA Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 12 LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 13 LAMEA Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 15 LAMEA Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 16 LAMEA Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 17 LAMEA Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 LAMEA Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 Brazil Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 22 Brazil Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 23 Brazil Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 24 Brazil Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 25 Brazil Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 26 Brazil Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 27 Argentina Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 28 Argentina Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 29 Argentina Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 30 Argentina Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 31 Argentina Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 32 Argentina Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 33 UAE Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 34 UAE Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 35 UAE Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 36 UAE Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 37 UAE Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 38 UAE Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 39 Saudi Arabia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 40 Saudi Arabia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 41 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 42 Saudi Arabia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 43 Saudi Arabia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 44 Saudi Arabia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 45 South Africa Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 46 South Africa Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 47 South Africa Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 48 South Africa Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 49 South Africa Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 50 South Africa Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 51 Nigeria Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 52 Nigeria Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 53 Nigeria Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 54 Nigeria Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Nigeria Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 56 Nigeria Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 57 Rest of LAMEA Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 58 Rest of LAMEA Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 59 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 60 Rest of LAMEA Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 61 Rest of LAMEA Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 62 Rest of LAMEA Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 63 Key Information – Novartis AG
TABLE 64 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 65 Key Information – Amgen, Inc.
TABLE 66 Key Information – Bristol Myers Squibb Company
TABLE 67 key Information – Karyopharm Therapeutics, Inc.
TABLE 68 Key Information – Gilead Sciences, Inc.
TABLE 69 Key information – Adaptimmune Limited
TABLE 70 Key Information – Genelux Corporation
TABLE 71 key information – Sarepta Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Novartis AG
FIG 3 Recent strategies and developments: Bristol Myers Squibb Company